Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06554873 · ClinicalTrials.gov registry record · Phase 3
Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders
A Phase 3 study, sponsored by Rose Research Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT06554873: Completed Phase 3 study, sponsored by Rose Research Center.
NCT06554873 is a Phase 3 study that has completed, run by Rose Research Center. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06554873, a Phase 3 study, has completed, sponsored by Rose Research Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
To determine whether smokers who initially respond (within 2 weeks) to nicotine products (including nicotine replacement therapy, e-cigarettes, nicotine pouches) by reducing their smoking by ≥50% can be successfully maintained on use of these noncombustible nicotine alternatives to cigarettes for 6 months, and whether this results in sustained smoking reduction/abstinence.
Primary Outcome
To determine whether maintained use of nicotine products can help sustain smoking abstinence rates for early responders. An expired air CO reading of ≤ 5 ppm at 24 weeks.
Interventions
- DRUG Nicoderm
- DRUG Nicorette 4Mg Chewing Gum
- DRUG Nicorette Lozenge Product
- OTHER NJOY e-cigarette
- OTHER on!
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-08-29 |
| Est. Completion | 2025-12-09 |
| Phase | Phase 3 |
What the finished NCT06554873 record still lists
NCT06554873 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 5 interventions - of which Nicoderm is the first listed.
NCT06554873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06554873 about?
NCT06554873 is a clinical study titled "Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders". To determine whether smokers who initially respond (within 2 weeks) to nicotine products (including nicotine replacement therapy, e-cigarettes, nicotine pouches) by reducing their smoking by ≥50% can be successfully maintained on use of these noncombustible nicotine alternatives to cigarettes for 6 ...
What is the current status of trial NCT06554873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2024-08-29. Estimated completion is 2025-12-09.
What interventions are being tested in trial NCT06554873?
The interventions under investigation include: Nicoderm (DRUG), Nicorette 4Mg Chewing Gum (DRUG), Nicorette Lozenge Product (DRUG), NJOY e-cigarette (OTHER), on! (OTHER).
Who is sponsoring clinical trial NCT06554873?
This trial is sponsored by Rose Research Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06554873's enrollment target sits among peer trials
150 1519th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI